Here, we can hypothetize that triptolide/Minnelide might be classified as a NF-κB inhibitor and thus could sensitize lung cancer to chemotherapy [31,92], radiotherapy [93], and TKIs [79]. The gene discussed is NFKB1; the disease is lung cancer.